Drug Search Results
More Filters [+]

CR-002

Alternative Names: cr-002, cr002, cr 002
Latest Update: 2024-10-29
Latest Update Note: News Article

Product Description

Alpha1 Proteinase Inhibitor for Cystic Fibrosis (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01347190)

Mechanisms of Action: PDGF Blocker

Novel Mechanism: Yes

Modality: Peptide/Protein

Route of Administration: Inhalant

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: CSL Behring
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CR-002

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: alpha 1-Antitrypsin Deficiency|Cystic Fibrosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CR002_1004

P1

Completed

alpha 1-Antitrypsin Deficiency|Cystic Fibrosis

2011-08-01

Recent News Events